目的观察血液透析联合血液灌流治疗维持性血液透析(MHD)患者顽固性高血压的临床效果。方法 40例透析龄>3个月合并顽固性高血压的MHD患者,随机分为试验组和对照组,各20例。对照组给予常规血液透析治疗,试验组给予血液透析联合血液灌流治疗。比较两组患者血压值。结果治疗前,试验组收缩压和舒张压分别为(186.1±8.0)、(96.0±6.9)mm Hg(1 mm Hg=0.133 k Pa),对照组分别为(185.9±8.1)、(95.5±7.7)mm Hg;治疗后试验组收缩压和舒张压分别为(141.0±5.9)、(78.1±6.5)mm Hg,对照组分别为(165.5±6.2)、(88.0±6.9)mm Hg;治疗后,两组患者收缩压和舒张压值低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。结论血液透析联合血液灌流对MHD患者顽固性高血压的控制作用良好,其安全、简便,值得推广。 Objective To observe the clinical effect of hemodialysis combined with hemoperfusion on refractory hypertension in maintenance hemodialysis (MHD) patients. Methods Forty MHD patients with dialysis age> 3 months and refractory hypertension were randomly divided into test group and control group, with 20 cases in each group. The control group was given routine hemodialysis, and the experimental group was given hemodialysis combined with hemoperfusion. Blood pressure was compared between two groups. Results Before treatment, systolic blood pressure and diastolic blood pressure in the experimental group were (186.1 ± 8.0) and (96.0 ± 6.9) mm Hg (1 mm Hg = 0.133 kPa), respectively, and were 185.9 ± 8.1 and 95.5 ± 7.7 ) mm Hg. After treatment, the systolic and diastolic blood pressures in the experimental group were (141.0 ± 5.9) and (78.1 ± 6.5) mm Hg respectively, while those in the control group were (165.5 ± 6.2) and (88.0 ± 6.9) mm Hg, Systolic blood pressure and diastolic blood pressure in both groups were lower than before treatment, and the experimental group was lower than the control group, the difference was statistically significant (P <0.05). Conclusion Hemodialysis combined with hemoperfusion has a good control effect on intractable hypertension in patients with MHD, which is safe and easy to be popularized.